Prävalenz der Insulinresistenz in Abhängigkeit vom Körpergewicht - Bedeutung für die Primärprävention kardiovaskulärer Erkrankungen

Zusammenfassung

Zwischen der Insulinresistenz (IR) und der Entstehung von Adipositas (A), metabolischem Syndrom (MS), Diabetes mellitus Typ II (DM) bzw. kardiovaskulären Erkrankungen (CVD) besteht ein enger, sich kontinuierlich negativ entwickelnder pathophysiologischer Zusammenhang, verbunden mit einer hohen Morbidität und Mortalität und einer weltweit epidemieartigen Zunahme der Fälle. Die IR korreliert andererseits auch unabhängig von A, MS und DM direkt mit CVD. Zur Erfassung der IR wird ein in praxi leicht durchführbarer Test benötigt. In einer Studie an 115 normgewichtigen, anscheinend gesunden Probandinnen und 555 übergewichtigen bzw. adipösen Patientinnen konnte gezeigt werden, dass durch Glukose- und Insulinbestimmungen im oralen Glukosetoleranztest (o-GTT) die IR zu 27,8 % frühzeitig (bei Normgewichtigen) und zu 91,9 % rechtzeitig (bei Übergewichtigen/Adipösen) erfasst werden kann. Die Normgrenzwerte liegen für Nüchtern-Glukose bei < 102 mg/dl und für Nüchtern-Insulin bei < 13 µU/ml. Der Nachweis/Ausschluss einer IR und damit die Primärprävention aller Folgeerkrankungen muss sehr früh einsetzen, optimal mit dem 20. Lebensjahr, mit Kontrollen alle fünf bis zehn Jahre, auch bei gesunden Normgewichtigen. Die lange Latenzphase (10 - 15 Jahre) zwischen dem Nachweis einer IR und dem Auftreten klinischer Symptome wirkt sich im Hinblick auf die Effektivität von Präventionsprogrammen günstig aus.

Abstract

Insulin resistance (IR) and the development of obesity, metabolic syndrome (MS), diabetes mellitus type II (DM) and cardiovascular diseases (CVD) are closely linked to high morbidity and mortality and an epidemic increase world wide. On the other hand IR is directly correlated with CVD, independent of obesity, MS and DM. To document IR an easily performed test method is necessary. In a study on 115 female test persons of normal weight and apparently healthy and 555 overweight/obese females, the following results were obtained using an oral tolerance test for the estimation of glucose and insulin. IR could be determined early in 27.8 % of patients of normal weight, and well-aimed in 91.9 % of patients who were overweight/obese and could be treated using primary or secondary prevention. Based on our results, it may be advisable to redefine the cut-off points for glucose (102 mg/dl) and insulin (13 µU/ml) values when screening for metabolic syndrome.

Insulinresistenz - oraler Glukosetoleranztest - Glukose- und Insulinbestimmung - kardiovaskuläre Erkrankungen - Primärprävention

Insulin resistance - oral tolerance test of glucose - glucose and insulin determination - cardiovascular diseases - primary prevention

Literatur

• 1 Reaven G M. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
• 2 Dunaif A, Segal K R, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.  Diabetes. 1989;  38 1165-1174
• 3 Yip J, Facchini F S, Reaven G M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.  JCEM. 1998;  83 2773-2776
• 4 Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes.  Diabetologia. 2000;  43 148-155
• 5 Yeni-Komshian H, Carantoni M, Abbasi F, Reaven G M. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.  Diabetes Care. 2000;  23 171-175
• 6 Facchini F S, Hua N, Abbasi F, Reaven G M. Insulin resistance as a predictor of age-related diseases.  JCEM. 2001;  86 3574-3578
• 7 Bergmann R N. Editorial: Insulin action and distribution of tissue blood flow.  JCEM. 2003;  88 4556-4558
• 8 McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G M. Use of metabolic markers to identify overweight individuals who are insulin resistent.  Ann Intern Med. 2003;  139 802-809
• 9 Reaven G M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease.  JCEM. 2003;  88 2399-2403
• 10 Kronmal R A, Barzilay J I, Tracy R P, Savage P J, Orchard T J, Burke G L. The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort.  JCEM. 2004;  89 2852-2858
• 11 Reaven G M. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals.  Endocrinol Metab Clin N Am. 2004;  33 283-303
• 12 Reaven G M. The insulin resistance syndrome: definition and dietary approaches to treatment.  Annu Rev Nutr. 2005;  25 17.1-17.16
• 13 Despres J P, Lamarche B, Mauriege P, Bernard C, Gilles D, Sital M, Lupien P J. Hyperinsulinemia as an independent risk factor for ischemic heart disease.  NEJM. 1996;  334 952-957
• 14 Zavaroni I, Bonini P, Gasparini A L, Barilli A, Zuccarelli E, Dall'Aglio E, Delsignore R, Reaven G M. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.  Metabolism. 1999;  48 989-994
• 15 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna R C, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study.  Diabetes. 1998;  47 1643-1649
• 16 Karelis A D, Pierre D HS, Conus F, Rabasa-Lhoret R, Poehlman E T. Metabolic and body composition factors in subgroups of obesity. What do we know?.  JCEM. 2004;  89 2569-2575
• 17 McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G M. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals.  Metabolism. 2004;  53 495-499
• 18 Alberti K GMM, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications.  Diabet Med. 1998;  15 539-553
• 19 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 20 Katz A, Nambi S S, Mather K. et al . Quantitative insulin sensitivity check index: a simple, accurate methode for assessing insulin sensitivity in humans.  JCEM. 2000;  85 2402-2410
• 21 Bergmann R N, Ader M, Huecking K, Van Citters G. Accurate assessment of β-cell function: the hyperbolic correction.  Diabetes. 2002;  51 S212-220
• 22 Quon M J. Editorial: Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity.  JCEM. 2001;  86 4615-4617
• 23 Abbassi F, Reaven G M. Evaluation of the quantitative insulin sensitivity check index as an estimate of insulin sensitivity in humans.  Metabolism. 2002;  51 235-237
• 24 Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome.  JCEM. 2004;  89 1273-1276
• 25 De Fronzo R A, Tobin J D, Andres R. Glucose clamp technique. A method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 E214-E223
• 26 Bergmann R N, Ider Y Z, Bowden C R, Cobelli C. Quantitative estimation of insulin sensitivity.  Am J Physiol. 1979;  236 E667-E677
• 27 Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M R, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes Care. 2001;  24 683-689
• 28 Bonora E, Targher G, Alberich M, Bonadonna R C, Saggiani F, Zenere M B, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
• 29 ATP III . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III).  JAMA. 2001;  285 2486-2497
• 30 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study.  Circulation. 2002;  105 310-315
• 31 Gutt M, Davis C L, Spitzer S B, Llabre M M, Kumar M, Czarnecki E M, Schneiderman N, Skyler J S, Marks J B. Validation of the insulin sensitivity index (ISL0, 120):comparison with other measures.  Diabetes Research and Clinical Practice. 2000;  47 177-184
• 32 Haffner S M, Miettinen H, Stern M P. The homeostasis model in the San Antonio Heart Study.  Diabetes Care. 1997;  20 1087-1092
• 33 Cree M G, Newcomer B R, Katsanos C S, Sheddield M, Chinkes D, Aarsland A, Urban R, Wolfe R R. Intramuscular and liver triglycerides are increased in the elderly.  JCEM. 2003;  89 3864-3871
• 34 Ostlund R E, Staten M, Kortt W M, Schultz D J, Malley M. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2-Cholesterol level in older adults.  NEJM. 1990;  322 29-34
• 35 Laakso M. How good a marker is insulin level for insulin resistance?.  Am J Epidemol. 1993;  137 959-965
• 36 Forst T, Standl E, Hohberg C, Konradt T, Schulze J, Strotmann H J, Lübbens G, Pahler S, Bachinger A, Langenfeld M, Pfützner A. IRIS II study: the IRIS II score-assessment of a new clinical algorithm for the classification of insulin resistance in patients with type 2 diabetes. Diabetes UK.  Diabetic Medicine. 2004;  21 1149-1153
• 37 Mykhänen L, Laakso M, Pyörälä K. High plasma insulin level associated with coronary heart disease in the elderly.  Am J Epidemiol. 1993;  137 1190-1202
• 38 Geisthövel F. Persönliche Mitteilung. 2004
• 39 Meier J J, Nauck M A, Schmidt W E, Gallwitz B. Diagnose einer eingeschränkten Glukosetoleranz und Diabetesprävention.  Deutsches Ärzteblatt. 2002;  23 A3182-3189
• 40 Schäfer-Graf U M, Vetter K. Screening, Diagnostik und Therapie des Gestationsdiabetes.  Der Gynäkologe. 2002;  35 652-660
• 41 ADA . Screening for Type 2 Diabetes.  Diabetes Care. 2004;  27 S47-S54
• 42 Eckardstein v A, Schulte H, Assmann G. Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM Study: implications for the definition of impaired fasting glucose by the American Diabetes Association.  JCEM. 2000;  85 3101-3108
• 43 Couthinho M, Gerstein H C, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events.  Diabetes Care. 1999;  22 233-240
• 44 Hu F B, Stampfer M J, Haffner S M, Solomon C G, Willet W C, Manson J E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.  Diabetes Care. 2002;  25 1129-1123
• 45 Hanefeld M. Fällt der Grenzwert?.  Medical Tribune. 2001;  36 3
• 46 Häring H U. Pathogenesis of type II diabetes: are there common causes for insulin resistance and secretion failure?.  Exp Clin Endocrinol Diabetes. 1999;  107 17-23
• 47 Carmina E, Lobo R A. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.  Fertil Steril. 2004;  82 661-665
• 48 Barbieri M, Rizzo M R, Manzella D, Paolisso G. Age-related insulin resistance: is it an obligatory finding? The lesson from healthy centenarians.  Diabetes Metab Res Rev. 2001;  17 19-26
• 49 Fernandez-Real J M, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome.  Endocrine Reviews. 2003;  24 279-301
• 50 Erdmann E, Hanefeld M. Glitazone - eine antidiabetische Substanzklasse aus kardiologischer Sicht.  Deutsches Ärzteblatt. 2004;  101 A2954-A2961
• 51 Goldstein B J, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function.  JCEM. 2004;  89 2563-2568
• 52 Choi K M, Lee K W, Kim S G, Park C G, Seo H S, Choi D J, Oh D S, Baik S H. Inflammation, insulin resistance, and glucose intolerance in acute myocardial infarction patients without a previous diagnosis of diabetes mellitus.  JCEM. 2005;  90 175-180
• 53 Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M. Relationship between insulin and carotid atherosclerosis in the general population.  Stroke. 1997;  28 1147-1152
• 54 Haffner S M, Williams K, Rozek M M, Stern P. Homeostasis model assessment insulin resistance in relation to 8-years of incidence of cardiovascular diseases.  Diabetologia. 2000;  43 1080
• 55 Windler E. Die Verantwortung des Frauenarztes in der Prävention von Herz-Kreislauf-Erkrankungen.  Frauenarzt. 2004;  45 735-739
• 56 Howard G, O'Leary D H, Zaccaro D, Haffner S M, Rewers M, Hamman R, Selby J V, Saad M F, Savage P, Bergmann R. Insulin sensitivity and atherosclerosis.  Circulation. 1996;  93 1809-1817
• 57 Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy R P, Haffner S M. Chronic subclinical inflammation as part of the insulin resistence syndrome: The Insulin Resistence Atherosclerosis Study (IRAS).  Circulation. 2000;  102 42-47
• 58 Pyörälä M, Miettinen H, Halone P, Laakso M, Pyörälä K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men.  Arterioscler Thromb Vasc Bio. 2000;  20 538-544
• 59 Bonora E, Targher G, Alberiche M, Bonadonna R C, Saggiani F, Zenere M B, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity.  Diabetes Care. 2000;  23 57-63
• 60 Hanley A JG, Williams K, Stern M P, Haffner S M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease.  Diabetes Care. 2002;  25 1177-1184
• 61 Matthaei S, Stumvoll M, Häring H-U. Thiazolidindione (Insulinsensitizer).  Deutsches Ärzteblatt. 2001;  98 A912-918
• 62 Abbasi F, Brown B W, Lamendola C, McLaughlin T, Reaven G M. Relationship between obesity, insulin resistance, and coronary heart disease risk.  J Am Coll Cardiol. 2002;  40 937-943
• 63 Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Heaften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.  Diabetes Care. 2000;  23 295-301
• 64 Olefsky J, Farquhar J W, Reaven G M, Alto P. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects.  Diabetes. 1973;  22 507-513
• 65 Norhammer A, Tenerz Ä, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus : a prospective study.  Lancet. 2002;  359 2140-2144
• 66 Zylka-Menhorn V. Viele Herzinfarktpatienten sind unerkannte Diabetiker.  Dtsch Ärzteblatt. 2004;  101 A2440-2443
• 67 Miettinen H, Lehto S, Salomaa V, Mähönen M, Niemelä M, Haffner S M, Pyörälä K, Tuomilehto J. Impact of diabetes on mortality after the first myocardial infarction.  Diabetes Care. 1998;  21 69-75
• 68 Bartnik M, Malmberg K, Norhammer A, Tenerz A, Öhrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.  European Heart Journal. 2004;  25 1990-1997
• 69 Lenz M, Müjlhauser I. Kardiovaskuläre Risikoschätzung für eine informierte Patientenentscheidung.  Med Klinik. 2004;  99 651-661
• 70 Bartnik M, Ryden L, Ferran R, Malmberg K, Pyörälä K, Simoons M, Standl E, Soler-Soler J, Öhrvik J. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe.  European Heart Journal. 2004;  25 1880-1890
• 71 Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigas J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries.  Lancet. 2004;  364 937